- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03540121
Video Education and Behaviour Contract to Optimize Adherence in Renal Transplants (VECTOR)
Improving Adherence in Kidney Recipients: a Randomized Controlled Trial of a Post-transplant Education Intervention
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Non-adherence to immunosuppressive medications is a major problem after kidney transplantation, leading to increased rejections, hospitalizations and health care expenditures. Effective educational opportunities may positively influence adherence, especially when combined with a behavior intervention. However, increasing education and support to transplant recipients demands greater use of care providers' time and resources in a health care system that is already stretched.
A patient-oriented video series has been developed according to best practices for transplant education, featuring an animated character embarking on a transplant journey. Animated segments illustrate difficult concepts for patients with poor health literacy, and patient narratives provide support and encouragement. A multicenter randomized controlled trial will be conducted with 4 sites across North America. Patients will be randomized (1:1) to either the intervention (i.e., home-based video education + adherence contract plus usual care) or usual care alone. Patients will be enrolled in the study prior to hospital discharge and will be provided with access to the video intervention and contract electronically. The primary outcome will be adherence at 12 months post-transplant, as measured by self-report (BAASIS), and variability in immunosuppressant levels. Secondary outcomes include the change in knowledge score between the intervention and control in groups (measured by the Kidney Transplant Understanding Tool); differences in self-efficacy (Generalized Self-efficacy Scale), beliefs about medicines (Beliefs of Medicine Questionnaire), and quality of life (SF-12). Individualized viewing statistics will be analyzed to determine patient uptake, and satisfaction about the educational experience will be captured on a self-reported survey.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada
- Southern Alberta Transplant Program
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada
- Saskatchewan Transplant Program
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois Health Sciences System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 or older
- can speak and understand and read English
- receive their first kidney transplant at one of the participating sites during enrolment
Exclusion Criteria:
- do not meet inclusion criteria
- have previously participated in a study entitle "Improving health outcomes of kidney recipients: A randomized controlled trial of a pre-transplant education intervention"
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Video education + adherence contract
electronically delivered video education (at transplant discharge) + electronic adherence contract (1 month after enrolment)
|
Participants will receive standard education along with the home-based video education plus an adherence contract.
Following the baseline assessment, access to videos will be provided electronically so that the patient can watch them at home.
The videos will be initially viewed in the following order: Video 1: Introduction, Video 2: Medications, Video 3: Your New Life.
Approximately one month after transplant, after the video series has been viewed in its entirety, participants will receive an email link inviting participants to reflect on their goals about transplantation and pledging to taking their medications as directed.
The contract will be non-enforceable, but it will provide patients with the opportunity to formally commit to a goal of taking the medications as prescribed.
At 3 months, and 12 months, the participant will have the opportunity to reflect and modify adherence goals as desired.
Other Names:
|
|
No Intervention: Standard education
standard of care education provided at each transplant center (control emails will be provided at intervention time points)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in adherence to immunosuppressant medications between intervention and control (self-report)
Time Frame: 3 months and 12 months after enrolment
|
The Basel Assessment of Adherence to Immunosuppressive medications (BAASIS) will be sent electronically by self-reported survey.
An answer of 'yes' to any of the questions (pertaining to missing doses, drug holidays, timing, and dose reduction) will constitute non-adherence as a binary outcome.
• A continuous measure of adherence will also be determined in each individual using a visual analogue scale.
|
3 months and 12 months after enrolment
|
|
Difference in adherence to immunosuppressant medications between intervention and control (immunosuppressant blood levels)
Time Frame: 3 months and 12 months after enrolment
|
Immunosuppressant levels (tacrolimus, cyclosporine or sirolimus) will be collected as per routine practice, and will be standardized to the patient specific target.
Intra-patient coefficients of variation (CV) will be used as a measure of trough level variability, and percentage of sub-therapeutic levels will be determined for each patient.
|
3 months and 12 months after enrolment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in changes in kidney transplant knowledge between intervention and control
Time Frame: 3 months and 12 months after enrolment
|
Measured by the Kidney Transplant Understanding Tool (K-TUT) via self-reported electronic survey.
The K-TUT consists of 9 true/false and 13 multiple-choice questions, and scores are based on the number correct answers [YES/ NO format] of 69 items.
|
3 months and 12 months after enrolment
|
|
Difference in quality of life between intervention and control
Time Frame: 3 months and 12 months after enrolment
|
Measured by the Short Form 12 (SF-12) via self-reported electronic survey.
The SF-12 is a 12-item psychometric scale that measures functional health and well-being.
Responses are indicated on a likert scale and aggregated into two sub scales; the mental component summary (MCS) and the physical component summary (PCS).
The scores are converted to adjusted norm-based values of a healthy individual with a midpoint score of 50 indicating average health comparable to norm values.
|
3 months and 12 months after enrolment
|
|
Difference in self efficacy between intervention and control
Time Frame: 3 months and 12 months after enrolment
|
Measured by the Generalized Self-Efficacy Scale (GSE) via self-reported electronic survey.
The GSE measures an individual's self-beliefs in their ability to cope with various demands in life.
It is a 10-item psychometric scale with a score for each item ranging from 1 to 4. The scores are summed and a higher score indicates stronger patient beliefs in self-efficacy.
|
3 months and 12 months after enrolment
|
|
Difference in education satisfaction between intervention and control
Time Frame: 3 months and 12 months after enrolment
|
Measured by self-report electronic survey
|
3 months and 12 months after enrolment
|
|
Difference in beliefs about medication between intervention and control
Time Frame: 3 months and 12 months after enrolment
|
Measured by the Beliefs of Medicine Questionnaire (BMQ) via self-reported electronic survey.
The BMQ is an 18-item psychometric questionnaire which consists of two subscales.
The BMQ-Specific assesses perceptions of medication prescribed for personal use, while the BMQ-General assesses beliefs about medications in general.
The BMQ-General can be further classified into domain of General-Harm and General-Overuse.
Items are scored on a 5-point likert scale, with higher score indicating stronger beliefs in each subscale.
|
3 months and 12 months after enrolment
|
|
Difference in adherence to transplant appointments between intervention and control
Time Frame: study end (12 months after enrolment)
|
Captured by chart review
|
study end (12 months after enrolment)
|
|
Video viewing habits (duration of viewing time)
Time Frame: study end (12 months after enrolment)
|
We will record the total duration that participants have watched each video (in minutes).
This number will be divided by the total length of each video and used as a surrogate marker for whether each video was watched in its entirety.
|
study end (12 months after enrolment)
|
|
Cost of administering the intervention
Time Frame: study end (12 months after enrolment)
|
Staff time and other resources used in administering the intervention will be tracked and monetized using market wages and prices.
|
study end (12 months after enrolment)
|
|
Days in hospital
Time Frame: study end (12 months after enrolment)
|
The number of days in hospital will be collected by chart review at the end of the study period to estimate health care utilization.
|
study end (12 months after enrolment)
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Mellon L, Doyle F, Hickey A, Ward KD, de Freitas DG, McCormick PA, O'Connell O, Conlon P. Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients. Cochrane Database Syst Rev. 2022 Sep 12;9(9):CD012854. doi: 10.1002/14651858.CD012854.pub2.
- Mansell H, Rosaasen N, West-Thielke P, Wichart J, Daley C, Mainra R, Shoker A, Liu J, Blackburn D. Randomised controlled trial of a video intervention and behaviour contract to improve medication adherence after renal transplantation: the VECTOR study protocol. BMJ Open. 2019 Mar 13;9(3):e025495. doi: 10.1136/bmjopen-2018-025495.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 99399
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.